Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
Of those vehicles, the ones that closed a merger.
Announced but not closed, and still hunting.
No closed vehicle here has both a stored price and a filed trust value to score it against.
2 liquidated — weigh against the wins.
2 vehicles on file, newest listing first
4 people on two or more of them
Douglas L. Braunstein is a veteran investment banker and corporate executive with over 35 years of experience in banking and finance, currently serving as Vice Chairman of Wells Fargo, a role he assumed in 2024. He is also the Founder and Managing Partner of Hudson Executive Capital (HEC), a value-oriented, constructive-engagement investment firm he established in 2015. At HEC, approximately forty current and former CEOs of publicly traded companies serve as both advisers and investors, and the firm has underwritten several successful SPAC offerings totaling approximately $1.6 billion. Through Hudson Executive Investment Corp., Braunstein served as Chairman and President across multiple SPAC vehicles, including Hudson Executive Investment Corp. II (HCII), which went public in March 2021 and raised $250 million, and Hudson Executive Investment Corp. III (HIII). The first Hudson Executive Investment Corp. completed a de-SPAC transaction valued at approximately $414 million, while both HCII and HIII were ultimately liquidated. Braunstein co-managed these SPACs alongside Joseph Bergeron.
Braunstein spent nearly two decades at JPMorgan Chase & Co., where he held a succession of senior leadership positions. He served as Vice Chairman from 2013 to 2014, Chief Financial Officer from 2010 to 2012, and as a member of the company's Operating Committee during the same period. Earlier at JPMorgan, he was Head of Americas Investment Banking and Global M&A from 2008 to 2010, Global Head of Industry Coverage from 2002 to 2007, and Head of M&A from 1997 to 2007. Prior to JPMorgan, Braunstein worked at Merrill Lynch, and he began his investment banking career at First Boston after reading a New York Times article about lawyers transitioning into investment banking. Over the course of his career, he has worked on transactions exceeding a trillion dollars in aggregate value. Earlier in his professional life, he had expected to become an academic, having attended Harvard Law School with the intention of becoming a law professor, but a failure to secure a Supreme Court clerkship redirected his path toward finance.
Braunstein earned a B.S. in Industrial and Labor Relations from Cornell University in 1983 and a J.D. from Harvard Law School. He has been deeply engaged with Cornell as a trustee, serving as Vice Chairman of the university, and as a member of its investment and finance committees as well as the ILR Dean's Advisory Council. He received the 2009 Alpern Award from Cornell and, in 2011, established the Braunstein Family Professorship at the ILR School, held by labor economist Lawrence Kahn. His corporate board service has been extensive. He served as Chairman of Talkspace, Inc. following its merger with Hudson Executive Investment Corp., and was a director and 10% owner of the company, holding approximately 13.6 million shares. He has also served as a director of Cantaloupe, Inc. since April 2020, where he sat on both the Compensation and Finance Committees; as a director of Eagle Pharmaceuticals, Inc. since July 2016, where he served on the Compensation Committee; and as a director and 10% owner of Cardtronics PLC, added in 2018. He was also a director of Corindus Vascular Robotics Inc., holding approximately 14.2 million shares. His estimated net worth has been reported at approximately $160 million, based on SEC filings. Now in his early sixties and based in the United States, Braunstein continues to be active in the healthcare finance space, speaking at industry events such as the 2025 Wells Fargo Healthcare Conference.
This record is keyed to SEC CIK 0001495110 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 18 institutional-holder rows on these vehicles, under 4 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.